This stock is just another dream. The earliest it can have a commercial product is mid 2016. By then QE will be over, interest rates will climb, and the market will be who knows where. The present valuation reminds me of the internet bubble in 1999-2000. The biotech bubble will pop sometime soon too.
This thread of messages is an interesting debate. After reading all posts, I'll side with Sanofi and the bulls. Also, after buying 12% at an average price of around $80 a share, likely Sanofi will buy more if the price goes much lower. Time is on our side.
Aren't you discounting the power of their platform/IP portfolio and applicability to many other medical conditions? Yes, their initial targets are rare, niche diseases, but the reason for the enthusiasm behind this stock is that they have a platform that could apply to many major medical conditions.
You are out of your mind. I've been investing in biotechs for over 20 years. I know an overvalued hype play when I see it. The first indication for this which company is pursuing is small. Yes they have good data, but the P3 clinical trial isn't going to be completed for 18 months. It is going to take another 6 months to compile the data and get the NDA filed. Then it is going to take 6 months more for an FDA decisionl. So you are looking at 30 months or 2.5 years. And then when they get approval, if they do, sales are going to be small. The only thing driving this stock is the new money entering the market as a result of QE. Well my friend that is coming to an end and so too will this overvalued stock price. And on top of all this, you have Obamacare totally screwing up the healthcare in this country. If you like to gamble with your money, this is the stock.